Abstract 428P
Background
A breast cancer risk assessment tool, utilizing a polygenic risk score based on 313 single nucleotide polymorphisms and a risk prediction algorithm from the Gail Model, has been established and validated for the Asian population. Facilitated focus group discussions were conducted to assess the preferences of women from two Asian countries regarding the presentation of risk results, the level of detail provided for explanations, and recommendations for follow-up actions.
Methods
This qualitative study took place from July to October 2022 to evaluate the perspectives of women in Indonesia and Singapore regarding personalized breast cancer risk assessment. Participants were presented with either a detailed high-risk or low-risk mock report and were then assigned to high-risk or low-risk result focus groups based on the report they received randomly. Thematic analysis was performed on the content of all focus group discussions.
Results
The majority of participants emphasized the importance of using non-intimidating visuals and incorporating a summary on the first page of the report to facilitate interpretation. Participants also recommended the use of simplified language to enhance communication styles. Notably, participants who received high-risk results reported feeling anxious, while those with low-risk results expressed relief. Overall, participants found the report valuable and expressed interest in similar reports covering other diseases in the future.
Conclusions
In conclusion, the study reveals that most patients prefer test reports that strike a balance between content and complexity. It highlights the psychological impact on patients receiving test results, which is greatly influenced by their level of understanding and interpretation of the reports. Additionally, the study suggests that increased patient engagement with physicians is likely following the receipt of test results. As a result, future research could be extended to include physicians directly involved in the delivery of breast cancer prevention care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Nalagenetics Pte Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract